What is Glenmark Pharmaceuticals Ltd's PE ratio?

Glenmark Pharmaceuticals Ltd trades at a P/E ratio of 22.00.

What is Glenmark Pharmaceuticals Ltd's market cap?

Glenmark Pharmaceuticals Ltd's market capitalisation is ₹68,784 Cr.

When did Glenmark Pharmaceuticals Ltd last report results?

Glenmark Pharmaceuticals Ltd last reported Q1FY27 results on 31 Jul '26.

What is Glenmark Pharmaceuticals Ltd's ROE?

Glenmark Pharmaceuticals Ltd's return on equity (ROE) is 23.6%.

What sector is Glenmark Pharmaceuticals Ltd in?

Glenmark Pharmaceuticals Ltd (GLENMARK) is classified in the Healthcare sector (Pharmaceuticals).

Healthcare · Pharmaceuticals

Glenmark Pharmaceuticals Ltd (GLENMARK)

₹2,451.90

Mkt cap

₹68,784 Cr

P/E ratio

22.00

P/B

6.59

Div yield

0.21%

ROE

23.60%

ROCE

39.80%

EPS (TTM)

₹111.45

Book value

₹372

52W range

1,810–2,515

Sector

Healthcare

Price history

Previous close

Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries. [1]

NSE GLENMARKBSE 532296

Health check

Constructive

ValuationCheap

ProfitabilityStrong

GrowthModerate

TechnicalsBullish

52-week range

−2.51% from high

₹2,452

₹1,810+35.43% from low₹2,515

Current

₹2,451.90

Prev close

₹2,437.20

Day

+0.60%

Price performance

+0.60%

−1.13%

+7.58%

+10.97%

+20.21%

+27.25%

YTD

+18.76%

Financials

Revenue, profit & margin

P/E ratio

22.0×

GLENMARK is 35% below the sector median of 34.0×

GLENMARK22.0×

Sector median34.0×

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	3,036	3,207	2,507	3,063	3,244	3,434	3,388	3,256	3,264	6,047	3,901	3,771	4,018
Expenses	2,599	2,745	2,715	2,559	2,656	2,832	2,787	2,695	2,684	3,687	3,031	3,008	3,214
Operating Profit	437	462	-209	504	588	602	600	561	581	2,360	870	763	805
OPM %	14%	14%	-8%	16%	18%	18%	18%	17%	18%	39%	22%	20%	20%
Other Income	-32	-205	87	351	31	39	31	-361	-297	-1,184	-140	-184	66
Interest	112	121	134	149	40	48	52	67	58	66	41	43	54
Depreciation	142	141	147	151	118	120	123	125	130	141	154	148	173
Profit before tax	151	-6	-403	555	462	473	456	8	96	967	534	388	643
Tax %	-14%	997%	-18%	319%	26%	25%	24%	45%	51%	37%	24%	22%	25%
Net Profit	173	-62	-331	-1,214	340	354	348	4	47	610	403	301	483
EPS in Rs	5.31	-2.90	-12.45	-43.17	12.06	12.55	12.33	0.16	1.66	21.63	14.29	10.68	17.11
Raw PDF

Earnings

Results dates & reactions

No upcoming results date on calendar.

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

Avg earnings-day move +0.10% · closed higher next day 20 of last 62

	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26	Q4FY26	Q1FY27
Broadcast	10 Nov '23◦	14 Feb '24◦	24 May '24◦	14 Aug '24◦	15 Nov '24◦	14 Feb '25◦	23 May '25◦	14 Aug '25◦	14 Nov '25◦	30 Jan '26◦	29 May '26◦	31 Jul '26◦
Earnings day	−6.87%	+1.64%	+8.06%	+5.00%	−3.13%	+3.84%	−2.12%	−3.46%	−1.41%	−4.74%	−3.24%	−0.17%
+1 day	−3.45%	+9.41%	+11.99%	+9.41%	−2.68%	+4.25%	−2.48%	−4.83%	−2.79%	−3.06%	−3.97%	−0.40%
+5 days	−0.03%	+14.46%	+13.53%	+13.11%	−0.80%	+0.16%	+5.44%	−4.33%	−2.81%	−2.06%	−4.33%	+0.78%
+15 days	+3.68%	+19.83%	+19.97%	+14.18%	+0.58%	+5.83%	+18.53%	+3.51%	+1.39%	+1.16%	−3.65%	+7.02%
+30 days	+9.97%	+23.81%	+31.18%	+13.04%	+5.27%	+16.79%	+30.97%	−4.49%	+7.08%	+6.45%	+1.33%	—
Filing	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	PDF	PDF	XBRL	XBRL	XBRL	XBRL

Corporate actions

Last 6 months

No recent corporate actions

Dividends, splits, and bonuses in the last six months show up here.

Results analysis

Shareholding

as of Jun 2026

46.65%Promoter

Promoters46.65%

FIIs20.89%0.54

DIIs18.60%0.68

Public13.81%0.11

Government0.04%

Ownership trend

Peers

8 companies

Valuation vs quality

P/E × ROCE · bubble = market cap

Name	CMP	P/E	Mkt Cap	Div Yld	NP Qtr	Qtr Profit Var	Sales Qtr	Qtr Sales Var	ROCE
SUNPHARMA	₹1,899.00	36.07	4,55,634	0.84%	2,901	+5.95%	15,300	+10.46%	20.53%
DIVISLAB	₹9,100.00	81.09	2,41,576	0.33%	902	+65.50%	3,080	+27.80%	21.97%
TORNTPHARM	₹4,857.00	82.80	1,84,745	0.78%	566	+5.79%	4,921	+54.85%	15.19%
CIPLA	₹1,385.00	31.26	1,11,888	0.94%	786	−39.19%	7,119	+2.33%	15.49%
ZYDUSLIFE	₹1,120.00	22.95	1,11,720	0.09%	990	−35.09%	8,017	+21.96%	21.14%
LAURUSLABS	₹1,840.00	90.93	99,417	0.11%	362	+125.49%	2,026	+29.10%	17.76%
LUPIN	₹2,110.00	16.20	96,483	0.85%	1,417	+16.08%	8,277	+32.04%	29.93%
GLENMARK	₹2,437.20	22.04	68,784	0.21%	483	+85.50%	4,018	+23.10%	39.77%
Median: 158 Co.	₹421.50	33.96	2,277	0.08%	13	+30.25%	164	+18.67%	14.96%

Filings

Annual reports15

Annual Report 2026bse Annual Report 2025bse Annual Report 2024bse Annual Report 2023bse Annual Report 2022bse Annual Report 2021bse Annual Report 2020bse Annual Report 2019bse Annual Report 2018bse Annual Report 2017bse Annual Report 2016bse Annual Report 2015bse Annual Report 2014bse Annual Report 2013nse Annual Report 2013bse

Credit ratings6

Rating update 12 Augcrisil Rating update 11 Febcrisil Rating update 18 Sep 2025crisil Rating update 23 Jul 2025fitch Rating update 18 Jun 2025crisil Rating update 25 Apr 2024fitch

Announcements5

Announcement under Regulation 30 (LODR)-Press Release / Media Release 21 Aug - Glenmark USA launched Calcium Gluconate Injection USP on August 21, 2026.Announcement under Regulation 30 (LODR)-Press Release / Media Release 20 Aug - Glenmark received U.S. FDA approval for Fluticasone Propionate Nasal Spray USP 0.05 mg/spray.Announcement under Regulation 30 (LODR)-Newspaper Publication 15 Aug - Newspaper Advertisement regarding the 48th Annual General Meeting ("AGM") to be held on Friday, September 11, 2026 at 2.00 p.m. through Video Conferencing ("VC") / …Letter To Shareholders Whose Email Address Are Not Registered Providing The Web Link Of Annual Report 13 Aug - 48th AGM scheduled for September 11, 2026; annual report and notice shared electronically.Business Responsibility and Sustainability Reporting (BRSR) 13 Aug - Glenmark filed FY26 BRSR; disclosed GST penalties including ₹16.20 crore, with appeals filed on most cases.